Impact of atypical coverage for patients with community-acquired pneumonia managed on the medical ward: Results from the United States community-acquired pneumonia project

Chris Frei, Jim M. Koeller, David S. Burgess, Robert Talbert, Michael T. Johnsrud

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Study Objective. As current guidelines for treatment of community-acquired pneumonia (CAP) recommend empiric antimicrobial coverage for atypical pathogens, we evaluated the need for atypical coverage by examining length of hospital stay (LOS) and mortality in patients with CAP who were managed on the medical ward. Methods. Medical records of patients with CAP admitted from January 1, 1997-December 31, 2001, from 176 United States nonteaching community hospitals were reviewed. Patients were divided into one of three mutually exclusive groups on the basis of intravenous antimicrobials received on days 1 or 2 of hospital stay: ceftriaxone monotherapy, ceftriaxone plus a macrolide, or levofloxacin. Variables evaluated for their ability to predict outcome were patient age, year of hospital admission, geographic region, preadmission setting, preadmission antimicrobial treatment, timing of antimicrobial administration, comorbid disease, and duration of intravenous antimicrobial treatment. The impact of initial antimicrobial regimen on LOS and mortality was evaluated in regression models while controlling for significant predictors of outcome. Results. Of 8975 patients evaluated, 2453 met the inclusion criteria. Significant differences were noted among patients who received ceftriaxone (932 patients), ceftriaxone plus a macrolide (872), and levofloxacin (649) with respect to mean ± SD age (72 ± 16, 67 ± 18, and 70 ± 17 yrs, respectively; p<0.0001), admission from a nursing home (21%, 11%, and 15%, respectively; p<0.0001), and duration of intravenous antimicrobial treatment (4.4 ± 2.7, 4.0 ± 2.6, and 3.6 ± 2.5 days, respectively; p<0.0001). The LOS predictors were age, geographic region, coexisting heart failure, and duration of intravenous antimicrobial therapy. Mortality predictors were age, admission from a nursing home, coexisting heart failure, and coexisting cancer. After controlling for these predictors of outcome, no significant differences were noted among the three groups for LOS (5.5 ± 3.5, 4.8 ± 2.9, and 4.8 ± 2.9 days, respectively; p=0.2791) or mortality (3.1%, 2.0%, and 2.6%, respectively; p=0.8461). Conclusion. Initial coverage for atypical pathogens does not affect LOS or mortality among patients with CAP managed on the medical ward.

Original languageEnglish (US)
Pages (from-to)1167-1174
Number of pages8
JournalPharmacotherapy
Volume23
Issue number9 I
DOIs
StatePublished - Sep 1 2003

Fingerprint

Length of Stay
Pneumonia
Ceftriaxone
Hospital Mortality
Levofloxacin
Macrolides
Nursing Homes
Heart Failure
Therapeutics
Mortality
Community Hospital
Medical Records
Guidelines

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Impact of atypical coverage for patients with community-acquired pneumonia managed on the medical ward : Results from the United States community-acquired pneumonia project. / Frei, Chris; Koeller, Jim M.; Burgess, David S.; Talbert, Robert; Johnsrud, Michael T.

In: Pharmacotherapy, Vol. 23, No. 9 I, 01.09.2003, p. 1167-1174.

Research output: Contribution to journalArticle

Frei, Chris ; Koeller, Jim M. ; Burgess, David S. ; Talbert, Robert ; Johnsrud, Michael T. / Impact of atypical coverage for patients with community-acquired pneumonia managed on the medical ward : Results from the United States community-acquired pneumonia project. In: Pharmacotherapy. 2003 ; Vol. 23, No. 9 I. pp. 1167-1174.
@article{df723261a88c4460a862c07417934828,
title = "Impact of atypical coverage for patients with community-acquired pneumonia managed on the medical ward: Results from the United States community-acquired pneumonia project",
abstract = "Study Objective. As current guidelines for treatment of community-acquired pneumonia (CAP) recommend empiric antimicrobial coverage for atypical pathogens, we evaluated the need for atypical coverage by examining length of hospital stay (LOS) and mortality in patients with CAP who were managed on the medical ward. Methods. Medical records of patients with CAP admitted from January 1, 1997-December 31, 2001, from 176 United States nonteaching community hospitals were reviewed. Patients were divided into one of three mutually exclusive groups on the basis of intravenous antimicrobials received on days 1 or 2 of hospital stay: ceftriaxone monotherapy, ceftriaxone plus a macrolide, or levofloxacin. Variables evaluated for their ability to predict outcome were patient age, year of hospital admission, geographic region, preadmission setting, preadmission antimicrobial treatment, timing of antimicrobial administration, comorbid disease, and duration of intravenous antimicrobial treatment. The impact of initial antimicrobial regimen on LOS and mortality was evaluated in regression models while controlling for significant predictors of outcome. Results. Of 8975 patients evaluated, 2453 met the inclusion criteria. Significant differences were noted among patients who received ceftriaxone (932 patients), ceftriaxone plus a macrolide (872), and levofloxacin (649) with respect to mean ± SD age (72 ± 16, 67 ± 18, and 70 ± 17 yrs, respectively; p<0.0001), admission from a nursing home (21{\%}, 11{\%}, and 15{\%}, respectively; p<0.0001), and duration of intravenous antimicrobial treatment (4.4 ± 2.7, 4.0 ± 2.6, and 3.6 ± 2.5 days, respectively; p<0.0001). The LOS predictors were age, geographic region, coexisting heart failure, and duration of intravenous antimicrobial therapy. Mortality predictors were age, admission from a nursing home, coexisting heart failure, and coexisting cancer. After controlling for these predictors of outcome, no significant differences were noted among the three groups for LOS (5.5 ± 3.5, 4.8 ± 2.9, and 4.8 ± 2.9 days, respectively; p=0.2791) or mortality (3.1{\%}, 2.0{\%}, and 2.6{\%}, respectively; p=0.8461). Conclusion. Initial coverage for atypical pathogens does not affect LOS or mortality among patients with CAP managed on the medical ward.",
author = "Chris Frei and Koeller, {Jim M.} and Burgess, {David S.} and Robert Talbert and Johnsrud, {Michael T.}",
year = "2003",
month = "9",
day = "1",
doi = "10.1592/phco.23.10.1167.32764",
language = "English (US)",
volume = "23",
pages = "1167--1174",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "9 I",

}

TY - JOUR

T1 - Impact of atypical coverage for patients with community-acquired pneumonia managed on the medical ward

T2 - Results from the United States community-acquired pneumonia project

AU - Frei, Chris

AU - Koeller, Jim M.

AU - Burgess, David S.

AU - Talbert, Robert

AU - Johnsrud, Michael T.

PY - 2003/9/1

Y1 - 2003/9/1

N2 - Study Objective. As current guidelines for treatment of community-acquired pneumonia (CAP) recommend empiric antimicrobial coverage for atypical pathogens, we evaluated the need for atypical coverage by examining length of hospital stay (LOS) and mortality in patients with CAP who were managed on the medical ward. Methods. Medical records of patients with CAP admitted from January 1, 1997-December 31, 2001, from 176 United States nonteaching community hospitals were reviewed. Patients were divided into one of three mutually exclusive groups on the basis of intravenous antimicrobials received on days 1 or 2 of hospital stay: ceftriaxone monotherapy, ceftriaxone plus a macrolide, or levofloxacin. Variables evaluated for their ability to predict outcome were patient age, year of hospital admission, geographic region, preadmission setting, preadmission antimicrobial treatment, timing of antimicrobial administration, comorbid disease, and duration of intravenous antimicrobial treatment. The impact of initial antimicrobial regimen on LOS and mortality was evaluated in regression models while controlling for significant predictors of outcome. Results. Of 8975 patients evaluated, 2453 met the inclusion criteria. Significant differences were noted among patients who received ceftriaxone (932 patients), ceftriaxone plus a macrolide (872), and levofloxacin (649) with respect to mean ± SD age (72 ± 16, 67 ± 18, and 70 ± 17 yrs, respectively; p<0.0001), admission from a nursing home (21%, 11%, and 15%, respectively; p<0.0001), and duration of intravenous antimicrobial treatment (4.4 ± 2.7, 4.0 ± 2.6, and 3.6 ± 2.5 days, respectively; p<0.0001). The LOS predictors were age, geographic region, coexisting heart failure, and duration of intravenous antimicrobial therapy. Mortality predictors were age, admission from a nursing home, coexisting heart failure, and coexisting cancer. After controlling for these predictors of outcome, no significant differences were noted among the three groups for LOS (5.5 ± 3.5, 4.8 ± 2.9, and 4.8 ± 2.9 days, respectively; p=0.2791) or mortality (3.1%, 2.0%, and 2.6%, respectively; p=0.8461). Conclusion. Initial coverage for atypical pathogens does not affect LOS or mortality among patients with CAP managed on the medical ward.

AB - Study Objective. As current guidelines for treatment of community-acquired pneumonia (CAP) recommend empiric antimicrobial coverage for atypical pathogens, we evaluated the need for atypical coverage by examining length of hospital stay (LOS) and mortality in patients with CAP who were managed on the medical ward. Methods. Medical records of patients with CAP admitted from January 1, 1997-December 31, 2001, from 176 United States nonteaching community hospitals were reviewed. Patients were divided into one of three mutually exclusive groups on the basis of intravenous antimicrobials received on days 1 or 2 of hospital stay: ceftriaxone monotherapy, ceftriaxone plus a macrolide, or levofloxacin. Variables evaluated for their ability to predict outcome were patient age, year of hospital admission, geographic region, preadmission setting, preadmission antimicrobial treatment, timing of antimicrobial administration, comorbid disease, and duration of intravenous antimicrobial treatment. The impact of initial antimicrobial regimen on LOS and mortality was evaluated in regression models while controlling for significant predictors of outcome. Results. Of 8975 patients evaluated, 2453 met the inclusion criteria. Significant differences were noted among patients who received ceftriaxone (932 patients), ceftriaxone plus a macrolide (872), and levofloxacin (649) with respect to mean ± SD age (72 ± 16, 67 ± 18, and 70 ± 17 yrs, respectively; p<0.0001), admission from a nursing home (21%, 11%, and 15%, respectively; p<0.0001), and duration of intravenous antimicrobial treatment (4.4 ± 2.7, 4.0 ± 2.6, and 3.6 ± 2.5 days, respectively; p<0.0001). The LOS predictors were age, geographic region, coexisting heart failure, and duration of intravenous antimicrobial therapy. Mortality predictors were age, admission from a nursing home, coexisting heart failure, and coexisting cancer. After controlling for these predictors of outcome, no significant differences were noted among the three groups for LOS (5.5 ± 3.5, 4.8 ± 2.9, and 4.8 ± 2.9 days, respectively; p=0.2791) or mortality (3.1%, 2.0%, and 2.6%, respectively; p=0.8461). Conclusion. Initial coverage for atypical pathogens does not affect LOS or mortality among patients with CAP managed on the medical ward.

UR - http://www.scopus.com/inward/record.url?scp=0141679668&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141679668&partnerID=8YFLogxK

U2 - 10.1592/phco.23.10.1167.32764

DO - 10.1592/phco.23.10.1167.32764

M3 - Article

C2 - 14524648

AN - SCOPUS:0141679668

VL - 23

SP - 1167

EP - 1174

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 9 I

ER -